PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.28%
Net income growth under 50% of CRVO's 50.68%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
720.76%
Some D&A expansion while CRVO is negative at -36.82%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
100.00%
Some yoy growth while CRVO is negative at -433.11%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-18.24%
Both cut yoy SBC, with CRVO at -63.48%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-114.66%
Negative yoy working capital usage while CRVO is 123.93%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-121.66%
Negative yoy AP while CRVO is 277.13%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
139.41%
Growth well above CRVO's 70.58%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-139.67%
Both negative yoy, with CRVO at -100.00%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-28.06%
Negative yoy CFO while CRVO is 12.22%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-383.87%
Negative yoy CapEx while CRVO is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-383.87%
We reduce yoy invests while CRVO stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-88.00%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.